BioNTech and Fosun Pharma have announced an agreement to supply mRNA with a new coronary nucleic acid vaccine in China

· The supply agreement reflects the shared commitment of the two companies, which have taken an important step towards achieving accessibility and affordability of high-quality new crown vaccines in China; To date, the mRNA new coronary nucleic acid vaccine BNT162b2 has been conducted in Phase II clinical trials in Jiangsu Province, China; (Shanghai, China and Mainz, Germany, December 16, 2020) BioNTech SE ("BioNTech" or "Company", NASDAQ Stock Code: BNTX) and Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma" or "Group", stock code: 600196. SH, 02196.HK) announced that the two sides have reached an agreement on the supply and production of the new mRNA coronary nucleic acid vaccine in Chinese mainland, and bioNTech expects to supply at least 100 million doses of BNT162 mRNA new coronary nucleic acid vaccine to Chinese mainland in 2021 in response to the new coronary pneumonia outbreak once the new coronary nucleic acid vaccine is approved by Chinese mainland.
vaccine will be supplied by BioNTech's production plant in Germany.
We would like to thank the Chinese government and the National Drug Administration for their support and trust in our vaccine development efforts to help address the threat of a global outbreak," said Dr. Uur Sahin, BioNTech's CEO and co-founder.
"s joint efforts with Fosun Pharma in vaccine development demonstrate the importance of global collaboration, which is an important part of our strategic plan to supply vaccines globally.
this supply agreement is an important step towards our common goal of delivering safe and effective vaccines to people around the world.
" Fosun Pharma Chairman and CEO Wu Yifang said, "Since the outbreak of the new crown, we have been working closely with BioNTech, in the State Council joint prevention and control mechanism, especially the State Drug Administration, the National Health Care Commission, the Ministry of Science and Technology and other relevant authorities concerned with the concern and support, quickly promote the mRNA new crown nucleic acid vaccine in China's clinical research and development work, and to ensure the safety and effectiveness of the vaccine in China under the premise of actively promoting the vaccine in China."
new coronary nucleic acid vaccine with BNT162b2 mRNA is a successful example of international research and development cooperation.
is pleased to have reached a future supply agreement with BioNTech in China, an important step forward for Fosun Pharma and BioNTech in their efforts to achieve accessibility and affordability of high-quality new crown vaccines in China.
" On March 13, 2020, BioNTech and Fosun Pharma reached a strategic cooperation agreement to jointly develop and commercialize vaccine products for the new coronavirus based on BioNTech's proprietary mRNA technology platform in Chinese mainland and Hong Kong, Macao and Taiwan.
launched a Phase II clinical trial of the candidate mRNA new coronary nucleic acid vaccine BNT162b2 in Taizhou and Sushui, Jiangsu Province, China, on November 24, 2020, which will recruit 960 healthy subjects aged 18 to 85 to assess the safety and immunogenicity of the vaccine to support future applications for the vaccine in China.
。